Pharmacokinetically guided sunitinib dosing: A feasibility study in patients with advanced solid tumours

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2441-2449

  Lankheet, N A G ^a   Kloth, J S L ^b   Gadellaa Van Hooijdonk, C G M ^c,d   Cirkel, G A ^c,d   Mathijssen, R H J ^b,d   Lolkema, M P J K ^c,d   Schellens, J H M ^d,e   Voest, E E ^c,d   Sleijfer, S ^b,d   De Jonge, M J A ^b,d   Haanen, J B A G ^e   Beijnen, J H ^a   Huitema, A D R ^a   Steeghs, N ^d,e  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Center for Personalised Cancer Treatment   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; N DEETHYLSUNITINIB; SUNITINIB;

ACUTE CORONARY SYNDROME; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; EPISTAXIS; FATIGUE; FEASIBILITY STUDY; FEMALE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; MOUTH PAIN; NAUSEA; ORAL MUCOSITIS; PERIORBITAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QT PROLONGATION; RASH; SIDE EFFECT; SKIN DISCOLORATION; SOLID TUMOR; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FATIGUE; FEASIBILITY STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; PYRROLES; SALVAGE THERAPY;

EID: 84900526150     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.194     Document Type: Article

References (30)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003a ) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478.
2. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK (2003 b) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care " therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 1011-1021.
3. Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F (2012) Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 30: 2046-2049.
4. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY (2012) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118: 1252-1259.
5. Beumer JH (2013) Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther 93: 228-230.
6. Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M, Cabanes L, Franck N, Blanchet B, Goldwasser F (2012) Variability of sorafenib toxicity and exposure over time: A pharmacokinetic/pharmacodynamic analysis. Oncologist 17: 1204-1212.
7. De Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH (2005) Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review. Clin Pharmacokinet 44: 147-173.
8. Demetri GD, Van Oosterom AT, Ga rrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety o f sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368: 1329-1338.
9. Eechoute K, Fransson MN, Reyners AK, De Jong FA, Sparrebo om A, Van Der Graaf WT, Friberg LE, Schiavon G, Wiemer EA, Verweij J, Loos WJ, Mathijssen RH, De Giorgi U (2012) A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patien ts. Clin Cancer Res 18: 5780-5787.
10. EMA (2007) Sutent: EPAR-scientific discussion. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Scientific-Discussion-Variation/human/000687/ WC500089487.pdf.
11. Engels FK Loos WJ Van Der Bol JM De Bruijn P Mathijssen RH Verweij J Mathot RA 2011 Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study Clin Cancer Res 17 353-362.
12. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ (2009) Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4068-4075.
13. Faivre S, Delbaldo C, Vera K, Robert C , Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhi bitor, in patients with cancer. J Clin Oncol 24: 25-35.
14. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H (2012) Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 30: 4017-4025.
15. George S, Blay JY, Casali PG, Le CA, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45: 1959-1968.
16. Houk BE, Bello CL, Poland B, R osen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66: 357-371.
17. Kloth JS, Klumpen HJ, Yu H, Eechoute K, Samer CF, Kam BL, Huitema AD, Daali Y, Zwinderman AH, Balakrishnar B, Bennink RJ, Wong M, Schellens JH, Mathijssen RH, Gurney H (2013) Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: The clearsun study. Clin Pharmacokinet; e-pub ahead of print 15 November 2013.
18. Klumpen HJ, Samer CF, Mathijssen RH, Schellens JH, Gurney H (2011) Moving towards dose individualisation of tyrosine kinase inhibitors. Cancer Treat Rev 37: 251-260.
19. Lankheet NA, Steeghs N, Rosing H, Schellens JH, Beijnen JH, Huitema AD (2013) Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mas s spectrometry: Validation and application in routine therapeutic drug monitoring. Ther Drug Monit 35: 168-176.
20. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor act i vity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337.
21. Mita AC, Papadopoulos K, De Jonge MJA, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QC, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK (2011) Erlot inib ?dosing-to-rash?: A phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer 105: 938-944.
22. Motzer RJ, Hutson TE, Olsen MR , Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012) Randomized phase II trial of sun itinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30: 1371-1377.
23. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, F iglin RA, GinsbergMS, KimST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-der ived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24.
24. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O?Farrell AM, Cherrington JM, Pryer NK (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20: 757-766.
25. Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R (2009) Phase II study of continuous daily sunitinib d osing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 101: 1543-1548.
26. Pond GR, Berry WR, Galsky MD, Wood BA, Leopold L, Sonpavde G (2012) Neutropenia as a potent ial pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 10: 239-245.
27. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib mala te for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513.
28. Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ (2013) Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53: 491-504.
29. Van Der Veldt AA, Boven E, Helgason HH, Van Wouwe M, Berkhof J, De Gast G, Mallo H, Tillier CN, Van Den Eertwegh AJ, Haanen JB (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99: 259-265.
30. Van Erp NP, Eechoute K, Van Der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, Van Der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H (2009) Pharma cogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27: 4406-4412.